BACKGROUND AND OBJECTIVES: Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1). METHODS:One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases). RESULTS:Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed. CONCLUSIONS: The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.
RCT Entities:
BACKGROUND AND OBJECTIVES: Treatment of high-grade MALT (mucosa-associated lymphoid tissue) gastric lymphoma remains uncertain. To assess efficacy and toxicity of the most common therapies--surgery followed by chemotherapy or chemotherapy alone--we began a controlled clinical trial in patients in early stage (I and II 1). METHODS: One hundred and two patients were randomized to be treated with surgery followed by six cycles of CEOP-Bleo (cyclophosphamide, epirubicin, vincristine, prednisone, and bleomycin at standard doses) (52 cases) or with chemotherapy alone (49 cases). RESULTS: Complete response rates were 94% [95% confidence interval (CI): 88-99%] and 96% (93-100%), respectively. Actuarial curves at 5 yr showed that event-free survival were 70% (95% CI: 59-74%) in patients treated with surgery and chemotherapy, that were not statistically significant to 67% (95% CI: 51-69%) in the patients who received chemotherapy (p = 0.5). Also, overall survival that was not statistically significant: 78% (95% CI: 70-88%) in the combined treatment and 76% (95% CI: 70-87%) in chemotherapy (p = 0.8). Acute and late toxicity were mild and well controlled. No acute leukemia or second neoplasm has been observed. CONCLUSIONS: The use of surgery and chemotherapy did not improve outcome in patients with early-stage high-grade gastric MALT lymphoma. It is apparent that chemotherapy alone is sufficient treatment in this select group of patients.
Authors: J C Vaillant; A Ruskoné-Fourmestraux; P Aegerter; B Gayet; J C Rambaud; P Valleur; R Parc Journal: Am J Surg Date: 2000-03 Impact factor: 2.565
Authors: P Koch; F del Valle; W E Berdel; N A Willich; B Reers; W Hiddemann; B Grothaus-Pinke; G Reinartz; J Brockmann; A Temmesfeld; R Schmitz; C Rübe; A Probst; G Jaenke; H Bodenstein; A Junker; C Pott; J Schultze; A Heinecke; R Parwaresch; M Tiemann Journal: J Clin Oncol Date: 2001-09-15 Impact factor: 44.544
Authors: W Fischbach; B Dragosics; M E Kolve-Goebeler; C Ohmann; A Greiner; Q Yang; S Böhm; P Verreet; O Horstmann; M Busch; E Dühmke; H K Müller-Hermelink; K Wilms; S Allinger; P Bauer; S Bauer; A Bender; G Brandstätter; A Chott; C Dittrich; K Erhart; D Eysselt; H Ellersdorfer; A Ferlitsch; M A Fridrik; A Gartner; M Hausmaninger; W Hinterberger; K Hügel; P Ilsinger; K Jonaus; G Judmaier; J Karner; E Kerstan; P Knoflach; K Lenz; A Kandutsch; M Lobmeyer; H Michlmeier; H Mach; C Marosi; W Ohlinger; H Oprean; H Pointer; J Pont; H Salabon; H J Samec; A Ulsperger; A Wimmer; F Wewalka Journal: Gastroenterology Date: 2000-11 Impact factor: 22.682
Authors: P G Gobbi; M L Ghirardelli; C Cavalli; L Baldini; C Broglia; V Clò; R Bertè; F Ilariucci; M Carotenuto; L Piccinini; C Stelitano; G Attardo-Parrinello; E Ascari Journal: Haematologica Date: 2000-04 Impact factor: 9.941
Authors: Richard W Tsang; Mary K Gospodarowicz; Melania Pintilie; Woodrow Wells; David C Hodgson; Alexander Sun; Michael Crump; Bruce J Patterson Journal: J Clin Oncol Date: 2003-11-15 Impact factor: 44.544
Authors: Ricardo Helman; Priscila Pereira dos Santos Teixeira; Carlos José Lazzarini Mendes; Thomas Szegö; Nelson Hamerschlak; Nelson Hamershlak Journal: Obes Surg Date: 2011-03 Impact factor: 4.129